{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=13", "query": { "intervention": "Arm 1- Dose Expansion", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 464, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:26:49.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03647163", "title": "Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Neuroendocrine Carcinoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "VSV-IFNβ-NIS", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab + nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-04-09", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647163" }, { "nct_id": "NCT02316509", "title": "A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2015-03-17", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Germantown, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316509" }, { "nct_id": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP2138", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2022-06-07", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 13, "location_summary": "Orange, California • Santa Monica, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05365581" }, { "nct_id": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Metastatic Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Small Cell Lung Cancer (SCLC)", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Lomvastomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2018-10-15", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03708328" }, { "nct_id": "NCT02876224", "title": "Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-09-30", "completion_date": "2019-06-25", "has_results": false, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 4, "location_summary": "Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02876224" }, { "nct_id": "NCT03084640", "title": "Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "CMP-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-05-04", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03084640" }, { "nct_id": "NCT05674175", "title": "Co-administration of CART22-65s and huCART19 for B-ALL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "B Lineage Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)", "type": "BIOLOGICAL" }, { "name": "Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stephan Grupp MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 93, "start_date": "2023-01-25", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05674175" }, { "nct_id": "NCT05537740", "title": "A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BAY3375968", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2022-10-11", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 4, "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537740" }, { "nct_id": "NCT05283720", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride [HCl]", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2022-06-14", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 18, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283720" }, { "nct_id": "NCT04294576", "title": "Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "BJ-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BJ Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2019-12-04", "completion_date": "2024-10-22", "has_results": false, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-11-15T12:26:49.365Z", "location_count": 5, "location_summary": "St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294576" } ] }